Literature DB >> 20976302

Oral Alendronate Treatment for Severe Polyostotic Fibrous Dysplasia due to McCune-Albright Syndrome in a Child: A Case Report.

Ana Luiza Andrade Aragão1, Ivani Novato Silva.   

Abstract

Polyostotic fibrous dysplasia (FD) associated to McCune-Albright Syndrome (MAS) often leads to fractures, deformities, and bone pain resulting in bad quality of life. Parenteral bisphosphonates have been used in children and adolescents to improve these symptoms with few adverse effects. We evaluated the response to oral Alendronate in a girl with severe MAS FD and observed improved quality of life with reduction of bone pain.

Entities:  

Year:  2010        PMID: 20976302      PMCID: PMC2952807          DOI: 10.1155/2010/432060

Source DB:  PubMed          Journal:  Int J Pediatr Endocrinol        ISSN: 1687-9848


  29 in total

1.  Efficacy and safety of oral alendronate treatment in children and adolescents with osteoporosis.

Authors:  Edip Unal; Ayhan Abaci; Ece Bober; Atilla Büyükgebiz
Journal:  J Pediatr Endocrinol Metab       Date:  2006-04       Impact factor: 1.634

2.  Bisphosphonate therapy in fibrous dysplasia.

Authors:  J M Lane; S N Khan; W J O'Connor; M Nydick; J P Hommen; R Schneider; E Tomin; J Brand; J Curtin
Journal:  Clin Orthop Relat Res       Date:  2001-01       Impact factor: 4.176

Review 3.  Fibrous dysplasia. Pathophysiology, evaluation, and treatment.

Authors:  Matthew R DiCaprio; William F Enneking
Journal:  J Bone Joint Surg Am       Date:  2005-08       Impact factor: 5.284

4.  Radiographic features of bisphosphonate therapy in pediatric patients.

Authors:  Leslie E Grissom; H Theodore Harcke
Journal:  Pediatr Radiol       Date:  2003-02-15

5.  Pharmacovigilance study of alendronate in England.

Authors:  Pipasha N Biswas; Lynda V Wilton; Saad A W Shakir
Journal:  Osteoporos Int       Date:  2003-04-23       Impact factor: 4.507

6.  Bone turnover in children and adolescents with McCune-Albright syndrome treated with pamidronate for bone fibrous dysplasia.

Authors:  G C Isaia; R Lala; C Defilippi; P Matarazzo; M Andreo; C Roggia; G Priolo; C de Sanctis
Journal:  Calcif Tissue Int       Date:  2002-07-23       Impact factor: 4.333

Review 7.  Clinical review 1: Bisphosphonate use in childhood osteoporosis.

Authors:  Laura K Bachrach; Leanne M Ward
Journal:  J Clin Endocrinol Metab       Date:  2008-11-25       Impact factor: 5.958

8.  Use of high-dose oral bisphosphonate therapy for symptomatic fibrous dysplasia of the skull.

Authors:  Kevin Chao; Laurence Katznelson
Journal:  J Neurosurg       Date:  2008-11       Impact factor: 5.115

9.  Acute effects of bisphosphonates on new and traditional markers of bone resorption.

Authors:  M Pedrazzoni; F S Alfano; C Gatti; M Fantuzzi; G Girasole; C Campanini; G Basini; M Passeri
Journal:  Calcif Tissue Int       Date:  1995-07       Impact factor: 4.333

Review 10.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

View more
  5 in total

1.  Intramedullary rod fixation of fibrous dysplasia without use of bisphosphonates.

Authors:  Greg Gaski; Dane Hansen; Leisel M Willis; Gary D Bos; John R Kean
Journal:  J Child Orthop       Date:  2013-09-03       Impact factor: 1.548

2.  Long-term efficacy of oral alendronate therapy in an elderly patient with polyostotic fibrous dysplasia: A case report.

Authors:  Gui-Dong Li; Akira Ogose; Tetsuo Hotta; Hiroyuki Kawashima; Takashi Ariizumi; Yongjun Xu; Naoto Endo
Journal:  Oncol Lett       Date:  2011-08-02       Impact factor: 2.967

3.  [Fibrous dysplasia: overview].

Authors:  Nessrine Akasbi; Fatima Ezzahra Abourazzak; Sofia Talbi; Latifa Tahiri; Taoufik Harzy
Journal:  Pan Afr Med J       Date:  2015-05-08

Review 4.  Clinical and translational pharmacological aspects of the management of fibrous dysplasia of bone.

Authors:  Marlous Rotman; Neveen Agnes Therese Hamdy; Natasha M Appelman-Dijkstra
Journal:  Br J Clin Pharmacol       Date:  2018-12-25       Impact factor: 4.335

5.  Pathological Femoral Shaft Fracture With McCune-Albright Syndrome With Hyperthyroidism Managed With Oral Alendronate: A Case Report.

Authors:  Kuldeep Bansal; Avijeet Prasad; Sumedha Singh; Ankita Chauhan; Shubham Singla
Journal:  Cureus       Date:  2022-07-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.